GlaxoSmithKline's (GSK) Influenza Vaccine FluLaval Quadrivalent Approved by FDA for Expanded Use in Children Ages Six Months and Older

Source Link:

http://www.gsk.com/en-gb/media/press-releases/2016/gsk-files-regulatory-submission-in-us-for-once-daily-closed-triple-combination-therapy-ffumecvi-for-patients-with-copd/